Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.76
-0.3400-5.57%
Post-market: 8.302.54+44.16%19:59 EST
Volume:6.21M
Turnover:36.36M
Market Cap:340.40M
PE:-1.54
High:6.06
Open:6.02
Low:5.73
Close:6.10
52wk High:9.60
52wk Low:3.81
Shares:59.10M
Float Shares:49.48M
Volume Ratio:3.48
T/O Rate:12.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7413
EPS(LYR):-3.7413
ROE:-50.93%
ROA:-16.50%
PB:1.04
PE(LYR):-1.54

Loading ...

Vanda Pharmaceuticals announces FDA approval of Bysanti tablets

TIPRANKS
·
Feb 21

US FDA approves Vanda's psychiatric drug

Reuters
·
Feb 21

Vanda Pharmaceuticals Announces FDA Approval of Bysanti™ (Milsaperidone) for the Treatment of Bipolar I Disorder and Schizophrenia - a New Chemical Entity Opening New Horizons in Psychiatric Innovation

THOMSON REUTERS
·
Feb 21

Vanda Pharmaceuticals Inc - Bysanti Expected to Be Commercially Available in Q3 2026

THOMSON REUTERS
·
Feb 21

Vanda Pharmaceuticals Inc: Includes Warning for Bysanti, Increased Mortality in Elderly Patients With Dementia-Related Psychosis

THOMSON REUTERS
·
Feb 21

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:17 PM

Reuters
·
Feb 21

Vanda Pharmaceuticals Sets 2026 Executive Salaries and Bonus Targets, Awards 2025 Bonuses and Equity Grants

Reuters
·
Feb 20

FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck

TIPRANKS
·
Feb 20

B. Riley Securities Keeps Their Buy Rating on Vanda (VNDA)

TIPRANKS
·
Feb 17

Cantor Fitzgerald Keeps Their Buy Rating on Vanda (VNDA)

TIPRANKS
·
Feb 15

Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals

TIPRANKS
·
Feb 13

Vanda Pharmaceuticals (VNDA) Q4 Loss Surge Challenges Bullish Valuation Narratives

Simply Wall St.
·
Feb 13

Vanda Pharmaceuticals Balances Growth With Rising Risks

TIPRANKS
·
Feb 13

BRIEF-Vanda Pharmaceuticals Inc Files For Mixed Shelf Offering Of Upto $200 Million - SEC Filing

Reuters
·
Feb 12

Vanda Pharmaceuticals Inc Files for Mixed Shelf Offering of Upto $200 Mln - SEC Filing

THOMSON REUTERS
·
Feb 12

Vanda Pharmaceuticals reports Q4 EPS ($2.39) vs. (8c) last year

TIPRANKS
·
Feb 12

Vanda Pharmaceuticals sees FY26 revenue $230M-$260M, consensus $271.27M

TIPRANKS
·
Feb 12

BRIEF-Vanda Pharmaceuticals Q4 EPS USD -2.39

Reuters
·
Feb 12

Vanda Pharmaceuticals Q4 Non-GAAP net loss hits USD 106.78 million

Reuters
·
Feb 12

Vanda Pharmaceuticals Inc - FY Revenue Guidance for Currently Commercialized Products Between $230 Mln to $260 Mln

THOMSON REUTERS
·
Feb 12